NCT05844202View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention

PHASE1CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

March 2, 2023

Study Completion Date

March 2, 2023

Conditions
Sars-CoV-2 Infection
Interventions
DRUG

Alveavax-v1.2

BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19

DRUG

Janssen Ad26.COV2.S

COVID-19 vaccine by Janssen / Johnson \& Johnson

Trial Locations (8)

1055

MERC Research Pty Ltd, Middelburg

1619

MERC Kempton Park, Kempton Park

1739

Ubuntu Clinical Research Center, Krugersdorp

1847

Ubuntu Clinical Research Center Lenasia, Lenasia

2090

NMMM Pharmmedica Health and Clinical Research, Johannesburg

7405

TASK applied Science Brooklyn Chest Hospital, Ysterplaat

9301

JOSHA Research, Bloemfontein

0152

Setshaba Research Centre, Soshanguve

All Listed Sponsors
lead

Alvea Holdings, LLC

INDUSTRY